As Pfizer Deal Speeds Up, Aurobindo Tangos With AstraZeneca For Branded Generics Play In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's Aurobindo Pharma is turning out to be a partner of choice for Big Pharma companies that intend to dig aggressively into emerging markets with a branded generics product portfolio
You may also be interested in...
Soriot Effect Sees AstraZeneca Selectively Scale Back Branded Generics In Emerging Markets
Leadership change is forcing the Anglo-Swedish drug giant to review its priorities in the branded generics business. AstraZeneca will invest selectively in countries where it has built a high base and shows ability to post robust growth.
With A New CEO, Will AstraZeneca Change Its Approach In Emerging Markets?
Roche’s surging growth in China could hint at what’s coming to AstraZeneca in emerging markets as Pascal Soriot, Roche’s head of pharmaceuticals, takes over at AZ.
AstraZeneca, Lilly, Novo Look To China Growth Despite Pricing Headwinds – Emerging Market Earnings Roundup (Part 1)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.